EGFL8 Inhibitors
Chemical inhibitors of EGFL8 act by targeting matrix metalloproteinases (MMPs), which are enzymes that play a crucial role in the remodeling of the extracellular matrix (ECM), a process in which EGFL8 is involved. Marimastat, as a broad-spectrum MMP inhibitor, can stabilize the ECM by preventing the degradation usually facilitated by MMPs, thereby inhibiting the functional activity of EGFL8. Similarly, GM6001, or Ilomastat, can hinder the ECM degradation, affecting the functional activity of EGFL8 associated with ECM modulation and cellular processes. Specific inhibitors like NSC 405020 and SB-3CT target MMP-2 and MMP-9, respectively, and by impeding these enzymes, they can disrupt the EGFL8-dependent pathways that contribute to ECM dynamics.
Moreover, inhibitors such as TAPI-0, which targets tumor necrosis factor-α converting enzyme (TACE) along with MMPs, can alter the interaction of EGFL8 with the ECM and affect cellular migration by impeding the MMP activity. Batimastat, another synthetic MMP inhibitor, can inhibit the role of EGFL8 in ECM remodeling. PD166793, offering a broad MMP inhibitory profile, can obstruct the degradation of the ECM, a key activity involving EGFL8, and thus inhibit its function in ECM remodeling. Ro 28-2653, which also inhibits MMPs, can lead to the functional inhibition of EGFL8 by disrupting angiogenesis-related processes. WAY-170523, a selective MMP-13 inhibitor, can influence ECM remodeling processes and thus inhibit EGFL8 activity. Lastly, AG3340 (Prinomastat) selectively targets MMPs to inhibit ECM degradation, which is instrumental in the functional activity of EGFL8, focusing on the ECM remodeling and related signaling. Each of these inhibitors, by modulating the activity of MMPs, can effectively inhibit the functional activity of EGFL8 in ECM-related processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. Given that EGFL8 has been implicated to play a role in extracellular matrix (ECM) remodeling, inhibition of MMPs by Marimastat can lead to the stabilization of the ECM, which can in turn inhibit the functional activity of EGFL8 in ECM degradation and remodeling processes. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
GM6001, also known as Ilomastat, functions as an inhibitor of MMPs. By inhibiting MMPs, GM6001 can prevent the degradation of the ECM, which is necessary for the proper functioning of EGFL8 in processes such as angiogenesis and wound healing. The inhibition of MMPs can therefore inhibit the functional activity of EGFL8 related to ECM modulation. | ||||||
NSC 405020 | 7497-07-6 | sc-477738 | 10 mg | $105.00 | ||
NSC 405020 is an MMP-2 inhibitor. EGFL8 activity is associated with MMP-2 mediated events in angiogenesis. By specifically inhibiting MMP-2, NSC 405020 can inhibit the functional role of EGFL8 in angiogenic processes. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $102.00 $388.00 | 15 | |
SB-3CT is a selective inhibitor of MMP-2 and MMP-9. EGFL8 is known to associate with MMP-mediated pathways, and by inhibiting MMP-2 and MMP-9, SB-3CT can disrupt the EGFL8-dependent processes that contribute to angiogenesis and tissue remodeling, thus functionally inhibiting EGFL8. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is a synthetic inhibitor of MMPs. By inhibiting the activity of MMPs, Batimastat can inhibit the functional role of EGFL8 in the remodeling of the ECM and in angiogenesis, as these processes are often regulated by MMP activity which is crucial for EGFL8 function. | ||||||
PD166793 | 199850-67-4 | sc-202709 | 5 mg | $150.00 | 6 | |
PD166793 is an MMP inhibitor with activity against a broad range of MMPs. By broadly inhibiting MMPs, PD166793 can hinder the ECM degradation, a process in which EGFL8 is involved, thus functionally inhibiting the activity of EGFL8 in ECM remodeling and angiogenic signaling. | ||||||
WAY 170523 | 307002-73-9 | sc-361402 sc-361402A | 1 mg 10 mg | $275.00 $595.00 | 1 | |
WAY-170523 is a selective inhibitor of MMP-13. Although MMP-13 is not the primary MMP associated with EGFL8, its inhibition can influence the overall ECM remodeling processes where EGFL8 is active, leading to the functional inhibition of EGFL8. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
AG3340, also known as Prinomastat, is a selective inhibitor of MMPs. By blocking the activity of MMPs, AG3340 inhibits the degradation of the ECM, a key process involving EGFL8, thereby leading to the functional inhibition of EGFL8 in the context of ECM remodeling and angiogenesis. | ||||||